Sarcopenia in Ovarian Cancer Patients, Oncologic Outcomes Revealing the Importance of Clinical Nutrition: Review of Literature

Author(s): Stefano Cianci*, Valerio Rumolo, Andrea Rosati, Giuseppe Scaletta, Salvatore Gueli Alletti, Taís Marques Cerentini, Zaki Sleiman, Patricia Lordelo, Daniela Angerame, Giorgia Garganese, Stefano Uccella, Mattia Tarascio, Giovanni Scambia

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 22 , 2019


Become EABM
Become Reviewer
Call for Editor

Abstract:

Introduction: Ovarian cancer is the leading cause of death among gynecological malignancies. Its usual clinical manifestation is at advanced stages, with nutritional impairment, weight loss, and a consequent decline in skeletal muscle mass and strength (defined as sarcopenia). The relationship between sarcopenia and decreased survival was demonstrated not only in ovarian cancer but also in other cancer types, such as hepatocellular, pancreatic, lung, colon, cervical, metastatic breast, and renal cancer. The aim of this study is to review the current evidence regarding the relationship between sarcopenia and the surgical and oncological outcomes in ovarian cancer patients.

Methods: The systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRSIMA) statement. The terms “SARCOPENIA” AND “OVARIAN CANCER” were systematically used to search PubMed and Scopus databases. Original reports in English language were identified, with the purpose to include all relevant papers regarding the role of sarcopenia and indicators of skeletal muscle quality assessment in gynecological ovarian cancer.

Results: A total of 9 studies were considered eligible for the present review. The strength of recommendation was moderate and the level of evidence was low in all selected articles. No prospective studies were conducted and most of the papers were case-control series comparing ovarian cancer sarcopenic population vs. non sarcopenic population.

Conclusions: Sarcopenia appears to have an important role in oncological outcomes of ovarian cancer patients. However, sarcopenia occurrence during disease history and mechanisms underlying the possible impairment in prognosis should be better investigated. Prospective trials are awaited in order to obtain a better insight in this topic.

Keywords: Ovarian cancer, sarcopenia, nutrition, body mass index, nutritional impairment, gynecological malignancies.

[1]
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19(8): 1893-907.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0437] [PMID: 20647400]
[2]
Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: Current approach to a challenging condition. Arch Gynecol Obstet 2019; 299(2): 299-315.
[http://dx.doi.org/10.1007/s00404-018-5006-z] [PMID: 30542793]
[3]
Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006; 107(1): 77-85.
[http://dx.doi.org/10.1097/01.AOG.0000192407.04428.bb] [PMID: 16394043]
[4]
Lo CS, Sanii S, Kroeger DR, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res 2017; 23(4): 925-34.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1433] [PMID: 27601594]
[5]
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20(5): 1248-59.
[http://dx.doi.org/10.1200/JCO.2002.20.5.1248] [PMID: 11870167]
[6]
Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2013; (2): CD008765
[http://dx.doi.org/10.1002/14651858.CD008765.pub3] [PMID: 23450588]
[7]
Paris I, Cianci S, Vizzielli G, et al. Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Hyperthermia 2018; 35(1): 370-4.
[http://dx.doi.org/10.1080/02656736.2018.1503346] [PMID: 30300042]
[8]
Leitao MM Jr, Chi DS. Surgical management of recurrent ovarian cancer. Semin Oncol 2009; 36(2): 106-11.
[http://dx.doi.org/10.1053/j.seminoncol.2008.12.002] [PMID: 19332245]
[9]
Cianci S, Ronsini C, Vizzielli G, et al. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. Updates Surg 2019; 71(2): 389-94.
[PMID: 30406932]
[10]
Bellia A, Vitale SG, Laganà AS, et al. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: A retrospective, multicenter analysis. Arch Gynecol Obstet 2016; 294(3): 615-22.
[http://dx.doi.org/10.1007/s00404-016-4087-9] [PMID: 27040423]
[11]
Cianci S, Abatini C, Fagotti A, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies using new hybrid CO2 system: Preliminary experience in referral center. Updates Surg 2019; 71(3): 555-60.
[http://dx.doi.org/10.1007/s13304-018-0578-5] [PMID: 30094567]
[12]
Cianci S, Vizzielli G, Fagotti A, et al. A novel HIPEC technique using hybrid CO2 recirculation system: Intra-abdominal diffusion test in a porcine model. Updates Surg 2018; 70(4): 529-33.
[http://dx.doi.org/10.1007/s13304-018-0557-x] [PMID: 29943156]
[13]
Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K. Advanced ovarian cancer: Primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: Primary debulking surgery and interval debulking surgery for advanced ovarian cancer. Oncologist 2016; 21(6): 745-54.
[http://dx.doi.org/10.1634/theoncologist.2015-0239] [PMID: 27009938]
[14]
Fagotti A, Costantini B, Gallotta V, et al. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: A retrospective cohort study on perioperative outcomes. J Minim Invasive Gynecol 2015; 22(3): 428-32.
[http://dx.doi.org/10.1016/j.jmig.2014.11.008] [PMID: 25461683]
[15]
Petrillo M, De Iaco P, Cianci S, et al. Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2016; 23(5): 1660-5.
[http://dx.doi.org/10.1245/s10434-015-5050-x] [PMID: 26714958]
[16]
Gallotta V, Conte C, Giudice MT, et al. Secondary laparoscopic cytoreduction in recurrent ovarian cancer: A large, single-institution experience. J Minim Invasive Gynecol 2018; 25(4): 644-50.
[http://dx.doi.org/10.1016/j.jmig.2017.10.024] [PMID: 29081384]
[17]
Gueli Alletti S, Vizzielli G, Lafuenti L, et al. Single-institution propensity-matched study to evaluate the psychological effect of minimally invasive interval debulking surgery versus standard laparotomic treatment: From body to mind and back. J Minim Invasive Gynecol 2018; 25(5): 816-22.
[http://dx.doi.org/10.1016/j.jmig.2017.12.007] [PMID: 29269126]
[18]
Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2013; 128(3): 573-8.
[http://dx.doi.org/10.1016/j.ygyno.2012.11.038] [PMID: 23219660]
[19]
Chan JL, Wang ET. Oncofertility for women with gynecologic malignancies. Gynecol Oncol 2017; 144(3): 631-6.
[http://dx.doi.org/10.1016/j.ygyno.2016.12.013] [PMID: 28012689]
[20]
Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. Fertility preservation in women with gynaecologic cancer: The impact on quality of life and psychological well-being. Hum Fertil (Camb) 2018; 21(1): 35-8.
[http://dx.doi.org/10.1080/14647273.2017.1339365] [PMID: 28625095]
[21]
Carter J, Stabile C, Gunn A, Sonoda Y. The physical consequences of gynecologic cancer surgery and their impact on sexual, emotional, and quality of life issues. J Sex Med 2013; 10(Suppl. 1): 21-34.
[http://dx.doi.org/10.1111/jsm.12002] [PMID: 23387909]
[22]
Laganà AS, La Rosa VL, Rapisarda AMC, Platania A, Vitale SG. Psychological impact of fertility preservation techniques in women with gynaecological cancer. E Cancer Med Sci 2017; 11Ed62
[http://dx.doi.org/10.3332/ecancer.2017.ed62] [PMID: 28275393]
[23]
Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: A message of hope for young women. Gynecol Oncol 2006; 103(3): 1109-21.
[http://dx.doi.org/10.1016/j.ygyno.2006.08.003] [PMID: 16996582]
[24]
Angarita AM, Johnson CA, Fader AN, Christianson MS. Fertility preservation: A key survivorship issue for young women with cancer. Front Oncol 2016; 6: 102.
[http://dx.doi.org/10.3389/fonc.2016.00102] [PMID: 27200291]
[25]
Vitale SG, La Rosa VL, Rapisarda AMC, Laganà AS. The importance of fertility preservation counseling in patients with gynecologic cancer. J Reprod Infertil 2017; 18(2): 261-3.
[PMID: 28868252]
[26]
Uccella S, Mele MC, Quagliozzi L, et al. Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications. Gynecol Oncol 2018; 149(2): 263-9.
[http://dx.doi.org/10.1016/j.ygyno.2018.03.044] [PMID: 29550182]
[27]
Tozzi R, Giannice R, Cianci S, et al. Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol 2015; 138(2): 252-8.
[http://dx.doi.org/10.1016/j.ygyno.2015.05.010] [PMID: 26003142]
[28]
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl. 6): Vi24-32.
[http://dx.doi.org/10.1093/annonc/mdt333] [PMID: 24078660]
[29]
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39(4): 412-23.
[http://dx.doi.org/10.1093/ageing/afq034] [PMID: 20392703]
[30]
Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011; 12(4): 249-56.
[http://dx.doi.org/10.1016/j.jamda.2011.01.003] [PMID: 21527165]
[31]
Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15(8): 2920-6.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-2242] [PMID: 19351764]
[32]
Peng PD, van Vledder MG, Tsai S, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 2011; 13(7): 439-46.
[http://dx.doi.org/10.1111/j.1477-2574.2011.00301.x] [PMID: 21689226]
[33]
Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012; 107(6): 931-6.
[http://dx.doi.org/10.1038/bjc.2012.350] [PMID: 22871883]
[34]
Kiyotoki T, Nakamura K, Haraga J, et al. Sarcopenia is an important prognostic factor in patients with cervical cancer undergoing concurrent chemoradiotherapy. Int J Gynecol Cancer 2018; 28(1): 168-75.
[http://dx.doi.org/10.1097/IGC.0000000000001127] [PMID: 29040185]
[35]
Vitale SG, Valenti G, Rapisarda AMC, et al. P16INK4a as a progression/regression tumour marker in LSIL cervix lesions: Our clinical experience. Eur J Gynaecol Oncol 2016; 37(5): 685-8.
[PMID: 29787011]
[36]
Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998; 85(1): 115-22.
[http://dx.doi.org/10.1152/jappl.1998.85.1.115] [PMID: 9655763]
[37]
Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33(5): 997-1006.
[http://dx.doi.org/10.1139/H08-075] [PMID: 18923576]
[38]
Hickson M. Nutritional interventions in sarcopenia: A critical review. Proc Nutr Soc 2015; 74(4): 378-86.
[http://dx.doi.org/10.1017/S0029665115002049] [PMID: 25923603]
[39]
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015; 350: G7647.
[http://dx.doi.org/10.1136/bmj.g7647] [PMID: 25555855]
[40]
Wright JD, Pawar N, Gonzalez JSR, et al. Scientific evidence underlying the American College of Obstetricians and Gynecologists’ practice bulletins. Obstet Gynecol 2011; 118(3): 505-12.
[http://dx.doi.org/10.1097/AOG.0b013e3182267f43] [PMID: 21826038]
[41]
Ataseven B, Luengo TG, du Bois A, et al. Skeletal muscle attenuation (sarcopenia) predicts reduced overall survival in patients with advanced epithelial ovarian cancer undergoing primary debulking surgery. Ann Surg Oncol 2018; 25(11): 3372-9.
[http://dx.doi.org/10.1245/s10434-018-6683-3] [PMID: 30069659]
[42]
Bronger H, Hederich P, Hapfelmeier A, et al. Sarcopenia in advanced serous ovarian cancer. Int J Gynecol Cancer 2017; 27(2): 223-32.
[http://dx.doi.org/10.1097/IGC.0000000000000867] [PMID: 27870708]
[43]
Conrad LB, Awdeh H, Acosta-Torres S, et al. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. J Surg Oncol 2018; 117(5): 1020-8.
[http://dx.doi.org/10.1002/jso.24990] [PMID: 29409111]
[44]
Silva de Paula N, de Aguiar Bruno K, Azevedo Aredes M, Villaça Chaves G. Sarcopenia and skeletal muscle quality as predictors of postoperative complication and early mortality in gynecologic cancer. Int J Gynecol Cancer 2018; 28(2): 412-20.
[http://dx.doi.org/10.1097/IGC.0000000000001157] [PMID: 29266018]
[45]
Kumar A, Moynagh MR, Multinu F, et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol 2016; 142(2): 311-6.
[http://dx.doi.org/10.1016/j.ygyno.2016.05.027] [PMID: 27235857]
[46]
Rutten IJG, Ubachs J, Kruitwagen RFPM, et al. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. Eur J Surg Oncol 2017; 43(4): 717-24.
[http://dx.doi.org/10.1016/j.ejso.2016.12.016] [PMID: 28159443]
[47]
Rutten IJG, van Dijk DPJ, Kruitwagen RFPM, Beets-Tan RG, Olde Damink SW, van Gorp T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle 2016; 7(4): 458-66.
[http://dx.doi.org/10.1002/jcsm.12107] [PMID: 27030813]
[48]
Rutten IJG, Ubachs J, Kruitwagen RFPM, Beets-Tan RGH, Olde Damink SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle 2017; 8(4): 630-8.
[http://dx.doi.org/10.1002/jcsm.12180] [PMID: 28513088]
[49]
Yoshikawa T, Takano M, Miyamoto M, et al. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol 2017; 80(3): 555-61.
[http://dx.doi.org/10.1007/s00280-017-3395-5] [PMID: 28726081]
[50]
Wall BT, Gorissen SH, Pennings B, et al. Aging is accompanied by a blunted muscle protein synthetic response to protein ingestion. PLoS One 2015; 10(11)E0140903
[http://dx.doi.org/10.1371/journal.pone.0140903] [PMID: 26536130]
[51]
Hernández Morante JJ, Gómez Martínez C, Morillas-Ruiz JM. Dietary factors associated with frailty in old adults: A review of nutritional interventions to prevent frailty development. Nutrients 2019; 11(1): 11.
[http://dx.doi.org/10.3390/nu11010102] [PMID: 30621313]
[52]
Dodd KM, Tee AR. Leucine and mTORC1: A complex relationship. Am J Physiol Endocrinol Metab 2012; 302(11): E1329-42.
[http://dx.doi.org/10.1152/ajpendo.00525.2011] [PMID: 22354780]
[53]
Begini P, Gigante E, Antonelli G, et al. Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis. Ann Hepatol 2017; 16: 107-14.
[http://dx.doi.org/10.5604/16652681.1226821]
[54]
Peng P, Hyder O, Firoozmand A, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012; 16(8): 1478-86.
[http://dx.doi.org/10.1007/s11605-012-1923-5] [PMID: 22692586]
[55]
Barber MD, Ross JA, Fearon KC. Cancer cachexia. Surg Oncol 1999; 8(3): 133-41.
[http://dx.doi.org/10.1016/S0960-7404(99)00045-6] [PMID: 11113664]
[56]
Tessier A-J, Chevalier S. An update on protein, leucine, omega-3 fatty acids, and vitamin D in the prevention and treatment of sarcopenia and functional decline. Nutrients 2018; 10(8): 10.
[http://dx.doi.org/10.3390/nu10081099] [PMID: 30115829]
[57]
Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care 2009; 12(1): 86-90.
[http://dx.doi.org/10.1097/MCO.0b013e32831cef8b] [PMID: 19057193]
[58]
Dardevet D, Rémond D, Peyron M-A, Papet I, Savary-Auzeloux I, Mosoni L. Muscle wasting and resistance of muscle anabolism: The “anabolic threshold concept” for adapted nutritional strategies during sarcopenia. ScientificWorldJournal 2012; 2012269531
[http://dx.doi.org/10.1100/2012/269531] [PMID: 23326214]
[59]
Boirie Y. Fighting sarcopenia in older frail subjects: Protein fuel for strength, exercise for mass. J Am Med Dir Assoc 2013; 14(2): 140-3.
[http://dx.doi.org/10.1016/j.jamda.2012.10.017] [PMID: 23181978]
[60]
Vitale SG, Capriglione S, Peterlunger I, et al. The role of oxidative stress and membrane transport systems during endometriosis: A fresh look at a busy corner. Oxid Med Cell Longev 2018; 20187924021
[http://dx.doi.org/10.1155/2018/7924021] [PMID: 29743986]
[61]
Ceccaroni M, Roviglione G, Bruni F, et al. Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: Prospective validation. “The times they are a-changin”? Surg Endosc 2018; 32(4): 2026-37.
[http://dx.doi.org/10.1007/s00464-017-5899-9] [PMID: 29052073]
[62]
Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010; 119(2): 259-64.
[http://dx.doi.org/10.1016/j.ygyno.2010.07.032] [PMID: 20800269]
[63]
Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol 2007; 197(6): 676.e1-7.
[http://dx.doi.org/10.1016/j.ajog.2007.10.495] [PMID: 18060979]
[64]
Huang D-D, Zhou C-J, Wang S-L, et al. Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer. Surgery 2017; 161(3): 680-93.
[http://dx.doi.org/10.1016/j.surg.2016.08.030] [PMID: 27712873]
[65]
Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: From sarcopenic obesity to cachexia. Clin Nutr 2014; 33(5): 737-48.
[http://dx.doi.org/10.1016/j.clnu.2014.03.007] [PMID: 24785098]
[66]
Cosquéric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 2006; 96(5): 895-901.
[http://dx.doi.org/10.1017/BJN20061943] [PMID: 17092379]
[67]
Capriglione S, Luvero D, Plotti F, et al. Ovarian cancer recurrence and early detection: May HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol 2017; 34(9): 164.
[http://dx.doi.org/10.1007/s12032-017-1026-y] [PMID: 28825178]
[68]
Plotti F, Scaletta G, Aloisi A, et al. Quality of life in platinum-sensitive recurrent ovarian cancer: Chemotherapy versus surgery plus chemotherapy. Ann Surg Oncol 2015; 22(7): 2387-94.
[http://dx.doi.org/10.1245/s10434-014-4263-8] [PMID: 25582738]
[69]
Plotti F, Montera R, Aloisi A, et al. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer. Eur J Surg Oncol 2016; 42(3): 383-90.
[http://dx.doi.org/10.1016/j.ejso.2015.12.001] [PMID: 26725211]
[70]
Capriglione S, Plotti F, Montera R, et al. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. Gynecol Oncol 2016; 143(3): 584-8.
[http://dx.doi.org/10.1016/j.ygyno.2016.10.006] [PMID: 27751589]
[71]
Plotti F, Scaletta G, Capriglione S, et al. The role of HE4, a novel biomarker, in predicting optimal cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 2017; 27(4): 696-702.
[http://dx.doi.org/10.1097/IGC.0000000000000944] [PMID: 28406844]
[72]
Cignini P, Vitale SG, Laganà AS, Biondi A, La Rosa VL, Cutillo G. Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates Surg 2017; 69(1): 75-82.
[http://dx.doi.org/10.1007/s13304-017-0418-z] [PMID: 28108938]
[73]
Angioli R, Plotti F, Capriglione S, et al. Preoperative local staging of endometrial cancer: The challenge of imaging techniques and serum biomarkers. Arch Gynecol Obstet 2016; 294(6): 1291-8.
[http://dx.doi.org/10.1007/s00404-016-4181-z] [PMID: 27535757]
[74]
Zanfagnin V, Ferrero A, Biglia N, et al. The role of surgery in recurrent endometrial cancer. Expert Rev Anticancer Ther 2016; 16(7): 741-50.
[http://dx.doi.org/10.1080/14737140.2016.1190650] [PMID: 27269480]
[75]
Vitale SG, Caruso S, Rapisarda AMC, Cianci S, Cianci A. Isoflavones, calcium, vitamin D and inulin improve quality of life, sexual function, body composition and metabolic parameters in menopausal women: Result from a prospective, randomized, placebo-controlled, parallel-group study. Przegl Menopauz 2018; 17(1): 32-8.
[http://dx.doi.org/10.5114/pm.2018.73791] [PMID: 29725283]
[76]
Caruso S, Cianci S, Vitale SG, Fava V, Cutello S, Cianci A. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Health Care 2018; 23(1): 24-31.
[http://dx.doi.org/10.1080/13625187.2018.1433824] [PMID: 29436865]
[77]
Cano A, Chedraui P, Goulis DG, et al. Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. Maturitas 2018; 107: 7-12.
[http://dx.doi.org/10.1016/j.maturitas.2017.10.004] [PMID: 29169584]
[78]
Caruso S, Rapisarda AMC, Cianci S. Sexuality in menopausal women. Curr Opin Psychiatry 2016; 29(6): 323-30.
[http://dx.doi.org/10.1097/YCO.0000000000000280] [PMID: 27584710]
[79]
Jamilian M, Foroozanfard F, Rahmani E, Talebi M, Bahmani F, Asemi Z. Effect of two different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients 2017; 9(12): 9.
[http://dx.doi.org/10.3390/nu9121280] [PMID: 29186759]
[80]
Salman H, Shah M, Ali A, Aziz A, Vitale SG. Assessment of relationship of serum neurokinin-B level in the pathophysiology of pre-eclampsia: A case-control study. Adv Ther 2018; 35(7): 1114-21.
[http://dx.doi.org/10.1007/s12325-018-0723-z] [PMID: 29923045]
[81]
Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause 2016; 23(1): 47-54.
[http://dx.doi.org/10.1097/GME.0000000000000485] [PMID: 26079974]
[82]
Laganà AS, Vitale SG, Stojanovska L, et al. Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy. Maturitas 2018; 109: 78-80.
[http://dx.doi.org/10.1016/j.maturitas.2017.12.015] [PMID: 29452786]
[83]
Caruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A. Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest 2015; 38(11): 1211-8.
[http://dx.doi.org/10.1007/s40618-015-0383-7] [PMID: 26337183]
[84]
Caruso S, Agnello C, Malandrino C, Lo Presti L, Cicero C, Cianci S. Do hormones influence women’s sex? Sexual activity over the menstrual cycle. J Sex Med 2014; 11(1): 211-21.
[http://dx.doi.org/10.1111/jsm.12348] [PMID: 24344697]
[85]
Castro A, González M, Tarín JJ, Cano A. Role of probiotics in obstetrics and gynecology. Nutr Hosp 2015; 31(Suppl. 1): 26-30.
[PMID: 25659051]
[86]
Di Tucci C, Di Feliciantonio M, Vena F, et al. Alpha lipoic acid in obstetrics and gynecology. Gynecol Endocrinol 2018; 34(9): 729-33.
[http://dx.doi.org/10.1080/09513590.2018.1462320] [PMID: 29726290]
[87]
Caruso S, Cianci S, Fava V, Rapisarda AMC, Cutello S, Cianci A. Vaginal health of postmenopausal women on nutraceutical containing equol. Menopause 2018; 25(4): 430-5.
[http://dx.doi.org/10.1097/GME.0000000000001061] [PMID: 29315133]
[88]
Caruso S, Cianci S, Vitale SG, Matarazzo MG, Amore FF, Cianci A. Effects of ultra low topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause 2017; 24(8): 900-7.
[http://dx.doi.org/10.1097/GME.0000000000000851] [PMID: 28350758]
[89]
Vitale SG, Laganà AS, Noventa M, et al. Transvaginal bilateral sacrospinous fixation after second recurrence of vaginal vault prolapse: Efficacy and impact on quality of life and sexuality. BioMed Res Int 2018; 20185727165
[http://dx.doi.org/10.1155/2018/5727165] [PMID: 29675427]
[90]
Halpern G, Schor E, Kopelman A. Nutritional aspects related to endometriosis. Rev Assoc Med Bras (1992) 2015; 61(6): 519-23.
[http://dx.doi.org/10.1590/1806-9282.61.06.519] [PMID: 26841161]
[91]
Pattanittum P, Kunyanone N, Brown J, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev 2016; 3CD002124
[PMID: 27000311]
[92]
Reyes-Muñoz E, Sathyapalan T, Rossetti P, et al. Polycystic ovary syndrome: Implication for drug metabolism on assisted reproductive techniques-a literature review. Adv Ther 2018; 35(11): 1805-15.
[http://dx.doi.org/10.1007/s12325-018-0810-1] [PMID: 30311070]
[93]
Caruso S, Cianci S, Cariola M, Fava V, Rapisarda AM, Cianci A. Effects of nutraceuticals on quality of life and sexual function of perimenopausal women. J Endocrinol Invest 2017; 40(1): 27-32.
[http://dx.doi.org/10.1007/s40618-016-0500-2] [PMID: 27300032]
[94]
Ter Borg S, de Groot LCPGM, Mijnarends DM, et al. Differences in nutrient intake and biochemical nutrient status between sarcopenic and nonsarcopenic older adults-results from the maastricht sarcopenia study. J Am Med Dir Assoc 2016; 17(5): 393-401.
[http://dx.doi.org/10.1016/j.jamda.2015.12.015] [PMID: 26825685]
[95]
Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013; 14(8): 542-59.
[http://dx.doi.org/10.1016/j.jamda.2013.05.021] [PMID: 23867520]
[96]
Deutz NEP, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clin Nutr 2014; 33(6): 929-36.
[http://dx.doi.org/10.1016/j.clnu.2014.04.007] [PMID: 24814383]
[97]
Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Endocrinol Metab 2007; 293(4): E923-31.
[http://dx.doi.org/10.1152/ajpendo.00314.2007] [PMID: 17609254]
[98]
Dirks-Naylor AJ, Lennon-Edwards S. The effects of vitamin D on skeletal muscle function and cellular signaling. J Steroid Biochem Mol Biol 2011; 125(3-5): 159-68.
[http://dx.doi.org/10.1016/j.jsbmb.2011.03.003] [PMID: 21397021]
[99]
Anagnostis P, Karras S, Goulis DG. Vitamin D in human reproduction: A narrative review. Int J Clin Pract 2013; 67(3): 225-35.
[http://dx.doi.org/10.1111/ijcp.12031] [PMID: 23294318]
[100]
Ross AC. The 2011 report on dietary reference intakes for calcium and vitamin D. Public Health Nutr 2011; 14(5): 938-9.
[http://dx.doi.org/10.1017/S1368980011000565] [PMID: 21492489]
[101]
Grosso G, Micek A, Marventano S, et al. Dietary n-3 PUFA, fish consumption and depression: A systematic review and meta-analysis of observational studies. J Affect Disord 2016; 205: 269-81.
[http://dx.doi.org/10.1016/j.jad.2016.08.011] [PMID: 27544316]
[102]
Marventano S, Kolacz P, Castellano S, et al. A review of recent evidence in human studies of n-3 and n-6 PUFA intake on cardiovascular disease, cancer, and depressive disorders: Does the ratio really matter? Int J Food Sci Nutr 2015; 66(6): 611-22.
[http://dx.doi.org/10.3109/09637486.2015.1077790] [PMID: 26307560]
[103]
Gray SR, Mittendorfer B. Fish oil-derived n-3 polyunsaturated fatty acids for the prevention and treatment of sarcopenia. Curr Opin Clin Nutr Metab Care 2018; 21(2): 104-9.
[http://dx.doi.org/10.1097/MCO.0000000000000441] [PMID: 29232264]
[104]
Lalia AZ, Dasari S, Robinson MM, et al. Influence of omega-3 fatty acids on skeletal muscle protein metabolism and mitochondrial bioenergetics in older adults. Aging (Albany NY) 2017; 9(4): 1096-129.
[http://dx.doi.org/10.18632/aging.101210] [PMID: 28379838]
[105]
Grosso G, Galvano F, Marventano S, et al. Omega-3 fatty acids and depression: Scientific evidence and biological mechanisms. Oxid Med Cell Longev 2014; 2014313570
[http://dx.doi.org/10.1155/2014/313570] [PMID: 24757497]
[106]
Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: A comprehensive meta-analysis of randomized clinical trials. PLoS One 2014; 9(5)E96905
[http://dx.doi.org/10.1371/journal.pone.0096905] [PMID: 24805797]
[107]
Woo J. Nutritional interventions in sarcopenia: Where do we stand? Curr Opin Clin Nutr Metab Care 2018; 21(1): 19-23.
[http://dx.doi.org/10.1097/MCO.0000000000000432] [PMID: 29045254]
[108]
Macciò A, Madeddu C, Massa D, et al. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med 2009; 13(9B): 3951-9.
[http://dx.doi.org/10.1111/j.1582-4934.2008.00408.x] [PMID: 18624749]
[109]
Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006; 176(8): 5023-32.
[http://dx.doi.org/10.4049/jimmunol.176.8.5023] [PMID: 16585599]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 22
Year: 2019
Published on: 26 September, 2019
Page: [2480 - 2490]
Pages: 11
DOI: 10.2174/1381612825666190722112808
Price: $65

Article Metrics

PDF: 52
HTML: 8